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Endocannabinoid/cannabinoid receptor signaling acts centrally and peripherally to govern appetite and
energy balance. While system stimulation promotes eating and energy storage, receptor blockade can
reduce food intake and facilitate weight loss. In this issue of Cell Metabolism, Addy et al. (2008) test the
therapeutic antiobesity potential of taranabant, a cannabinoid 1 receptor inverse agonist.Work over recent years has identified the
cannabinoid receptors as mediators of
the pharmacological actions of the phyto-
cannabinoid molecules present in Canna-
bis sativa. Additional efforts have uncov-
ered biologically active lipid compounds,
the endogenous cannabinoids, that are
these receptors’ natural ligands. The ‘‘en-
docannabinoids’’ have now been linked
to numerous physiological and psycholog-
ical processes, from nociception, thermo-
regulation, and cell proliferation to emotion
and cognition. Importantly, the rapid ad-
vances in this field have been greatly aided
by the availability of antagonists/inverse
agonistsselective forcannabinoid1 recep-
tors (CB1Rs) expressed in the brain and
peripheral tissues.
Among marijuana’s many psychologi-
cal effects, a well-recognized action is
the induction of a strong desire to eat,
together with an increased anticipation
of the delights of food and enhanced en-
joyment of its sensory properties. These
effects reflect the role of anandamide
and other endocannabinoids in the nor-
mal, physiological processes that govern
appetite. Endocannabinoids appear to be
directly involved in the central mecha-
nisms that give rise to hunger, food crav-
ing and anticipation, and the hedonic
evaluation of food (Kirkham, 2005). The
clinical potential of these pathways was
highlighted by early reports that the CB1
antagonist rimonabant could suppress
food intake in animal models—presum-
ably by blocking the actions of endo-
cannabinoids within feeding- and re-
ward-related brain circuits (Arnone et al.,
1997). Pharmaceutical companies were
thus alerted to a potential new class of
antiobesity drugs that could, by modify-
ing endocannabinoid actions, reduce thedrive to eat and the tendency to overcon-
sume.
Rimonabant is currently licensed in
many countries (although not the USA)
as an adjunct to diet and exercise for the
treatment of overweight or obese patients
with associated conditions, such as type
2 diabetes and dyslipidemia, and has
proven reasonably effective in improving
these parameters. The mechanism of ac-
tion, initially predicated on its anorectic
actions, remains uncertain, with recent
attention focusing on peripheral meta-
bolic factors. In preclinical studies, rimo-
nabant’s anorectic effects were relatively
short lived, while weight loss persisted
with continued treatment (Ravinet Trillou
et al., 2003). In addition, the drug’s bene-
ficial effects (including improved plasma
glucose, low-density lipoprotein choles-
terol, and free fatty acidprofiles) exceeded
the consequences expected solely from
reduced food consumption and lowered
body weight. In fact, endocannabinoids
appear to act at receptors in adipocytes,
liver, pancreas, and muscle to modulate
the regulation of energy utilization and
fuel storage, with rimonabant and its ana-
logs promoting lipolysis and increasing
energy expenditure (Kunos, 2007; Cota,
2007).
In this issue, Heymsfield and colleagues
(Addy et al., 2008) report preliminary find-
ings on the weight-reducing and meta-
bolic effects of Merck’s novel CB1R
inverse agonist taranabant in overweight
and obese subjects. In an acute 24-hour
food intake study, taranabant (12 mg)
was found to significantly suppress ad
libitum food intake, reducing caloric in-
take over 24 hr by approximately 20%
compared to placebo. A parallel indirect
calorimetry study also found a modestCell Metabincrease in resting energy expenditure
with a significant decrease in respiratory
quotient, implying a drug-induced in-
crease in fat oxidation.
In a 12-week dose range-finding study,
taranabant was administered in conjunc-
tion with a reduced-calorie diet plan. Here,
each dose produced a persistent decline
inbodyweight over the full courseof theex-
periment. In those subjects completing the
treatment, doses of 0.5 to 6 mg taranabant
produced weight loss between 3.6 and
6.3 kg, compared to 1.4 kg with placebo.
These effects compare favorably with the
weight loss obtained in far longer phase 3
clinical trials of 10 or 20 mg doses of rimo-
nabant (Van Gaal et al., 2005; Pi-Sunyer
et al., 2006).
In light of the current regulatory climate
and continuing concerns over the safety
of this class of drugs, Addy et al. (2008)
are rightly cautious in describing the rela-
tive efficacy of taranabant for weight loss
and the incidence and nature of the drug’s
side effects—particularly psychiatric con-
sequences reminiscent of those hindering
rimonabant in its bid for FDA approval
(Christensen et al., 2007). Reflecting the
ubiquity of CB1Rs in the gastrointestinal
tract, taranabant treatment was associ-
ated with an increase in gastrointestinal
symptoms. More influential in determin-
ing treatment continuation, however,were
adversepsychiatric effects, including anx-
iety, irritability, and depressed mood—
again, consistent with the central distribu-
tion of cannabinoid receptors. Although
the trends in these and related factors
were small and not statistically reliable,
any increase in incidence would have
potentially immense clinical significance
when multiplied across a potential patient
population ofmanymillions.Moredetailedolism 7, January 2008 ª2008 Elsevier Inc. 1
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Previewsanalyses of the effects of taranabant
on mood-related factors are therefore
imperative.
Overall, the Addy et al. (2008) report
confirms that CB1-selective antagonists/
inverse agonists may provide a relatively
effective alternative to existing antiobesity
drugs through possible effects on food
intake, and also on energy storage and
metabolism. However, as the authors
observe, many aspects of cannabinoid
antagonist action remain to be elucidated.
In particular, better characterizations of
the effects on appetite and behavior are
needed.What changes in hunger, sensory
evaluation of food, and/or satiety under-
pin the observed reduction in food intake?
Do the effects reflect changes in routine
appetite-related psychological factors, or
are there nonspecific, indirect effects of
the drug? As a not altogether facetious
aside, pruritus (itching) was a side effect
reported by a large number of taranabant
patients and in some cases led to discon-
tinuation from the trial. Increased levels
of scratching contribute to the intake sup-
pression observed in rodents treated with
this class of drugs (Tallett et al., 2007),
suggesting an alternative explanation that
may subvert accepted notions of how
the drugs affect eating. This example
highlights the need, when evaluating can-
nabinoid-based pharmacotherapies, to
consider the broad spectrum of physi-
ological and behavioral processes sub-
served by endocannabinoids and to de-
termine the specificity of their actions.
In the animal laboratory, motivational
specificity can only be inferred indirectly
from behavior. Clinical trials thus provide2 Cell Metabolism 7, January 2008 ª2008 Ean important opportunity to obtain sub-
jective reports about drug effects and,
crucially, apply fine-resolution measures
of appetite and eating behavior. Although
Addy et al. (2008) indicate that ratings of
hunger and other appetite-related param-
eters were assessed for the acute study,
no data are reported. In the chronic study,
only periodic, retrospective measures of
appetite and satiety were made, which
detected no significant trends. However,
we cannot discount important, possibly
subtle changes potentially identifiable by
more detailed, proximal measures of eat-
ing behavior. Laboratory animals treated
repeatedly with rimonabant or tarana-
bant showmarkedly diminished anorectic
effects over time; it remains unclear
whether this same effect is observed clin-
ically, but such data are clearly crucial to
our understanding of the drug’s antiobe-
sity action. If taranabant does act sepa-
rately on appetite and metabolic factors,
their relative contributions to weight loss
need to be carefully assessed.
Ultimately, only a deeper knowledge of
central and peripheral endocannabinoid
mechanisms can improve our theoretical
models and allow better targeting and
more effective administration of these
drugs for obesity/metabolic syndrome
management. The current state of our
knowledge is highlighted by a literature
search for ‘‘cannabinoids and obesity’’:
nearly half the articles are reviews. Many
of these speculate on the therapeutic
potential of CB1 antagonists/inverse ago-
nists, extrapolating from relatively sparse
empirical data from animal or in vitro
models. Endocannabinoids do appear tolsevier Inc.be important in the control of appetite
and regulation of energy balance and
could be key to the future pharmaceutical
management of obesity and its comorbid-
ities; the recent work by Addy et al. (2008)
indicates this potential clearly. But the
race to market might be reined in to
follow, rather than lead, the development
of satisfactory theoretical models about
their function.
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